Joint Formulary & PAD

Amikacin liposomal - Bacterial lung infection (non-cystic fibrosis)

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Inhalation
Associated Icons :
NHSE
SPC
Restrictions / Comments :
Important
Follow local guidelines on the use of antimicrobials

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Amikacin liposomal
Indication :
Bacterial lung infection (non-cystic fibrosis)
Group Name :
Keywords :
antibiotic, antibacterial, aminoglycoside
Brand Names Include :
Arikayce Liposomal
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0

Committee Recommendations (1)

This drug is currently not on the APC workplan. The APC will consider recommending prescribing of this treatment upon submission of a formal request with its associated evidence. Please contact your local CCG Medicines Management team OR formulary pharmacist at your acute trust, if you wish to make a submission. 
This drug / device has not yet been evaluated by NICE or the Surrey and North West Sussex Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing this drug.

Other Indications

Below are listed other indications that Amikacin liposomal is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Bacterial lung infection (non-cystic fibrosis).

  • No records returned.